Endocare Horizon urology stent clinicals to be under way in first half of 1998, CEO tells investors.
This article was originally published in The Gray Sheet
Executive Summary
ENDOCARE UROLOGY STENT CLINICALS ON HORIZON FOR FIRST HALF OF 1998, Paul Mikus, chairman and CEO, stated at an Oct. 29 session of the Oppenheimer & Co. health care conference in New York City. The Horizon stent studies will evaluate the device in preventing urine retention caused by swelling after thermal treatment of benign prostatic hyperplasia.